Objectives: Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some of the pitfalls with dexmedetomidine as the sole agent, there are an increasing number of reports regarding its combination with ketamine. This article provides a descriptive account of the reports from the literature regarding the use of a combination of dexmedetomidine and ketamine for procedural sedation.
I
nvasive and noninvasive procedures remain a component in the management of children with acute and chronic diseases. In recent years there has been a shift in the philosophy regarding procedural sedation given the increasing recognition of the negative aspects of inadequate sedation. Therefore, more patients are being sedated for procedures and the depth of sedation achieved is increasing in certain environments. Regardless of the procedure, there are several options for the agent or agents chosen for sedation. In the general practice of procedural sedation, propofol is a frequently chosen agent because it can be easily titrated by continuous infusion, is generally effective, and allows for rapid awakening once the procedure is completed. However, in patients with comorbid respiratory or cardiovascular diseases, there may be a relatively high incidence of respiratory effects, including hypotension, hypoventilation, upper airway obstruction, and apnea (1) (2) (3) (4) (5) (6) . Although these effects are generally dose-dependent and more likely with higher doses as deeper levels of sedation/anesthesia are achieved, there is significant interpatient variability regarding the potential for adverse effects (7) . Given these concerns, the search for alternative agents continues.
Dexmedetomidine (Precedex; Hospira Worldwide, Lake Forest, IL) exerts its physiologic effects through the α 2 -adrenergic receptor system. Initial Food and Drug Administration approval in the United States for the administration of dexmedetomidine occurred in 1999. At that time, approval was granted for the sedation of adults during mechanical ventilation. Additional approval was granted in 2009 for monitored anesthesia care in adults. Although Food and Drug Administration-approved only for use in adults, dexmedetomidine continues to be used successfully in several different clinical scenarios in infants and children, including procedural sedation (8) . Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures (9) (10) (11) (12) (13) . In the first prospective evaluation of dexmedetomidine as the sole agent during an invasive procedure in infants and children, Munro et al (9) reported their experience with dexmedetomidine during cardiac catheterization. After oral premedication with midazolam and the placement of intravenous access, dexmedetomidine was administered as a loading dose of 1 μg/kg over 10 mins, followed by an infusion of 1 μg/kg/hr titrated up to 2 μg/ kg/hr as needed. Five of the 20 patients (25%) moved during local infiltration of the groin, which did not require treatment or interfere with cannulae placement. Twelve (60%) patients received a propofol bolus during the procedure for movement, an increasing bispectral index number, or anticipation of a stimulus. Subsequent studies in the adult population have similarly demonstrated that dexmedetomidine may not be the optimal agent for painful procedures. Jalowiecki et al (10) reported that dexmedetomidine was ineffective during colonoscopy in adults and was associated with a high incidence of adverse effects, including a prolonged delay in discharge times. The authors closed the study before completion (12) . Similar issues were encountered when comparing dexmedetomidine with midazolam for monitored anesthesia care in adults during cataract surgery (13) .
In specific clinical scenarios, the response to failures with usual doses (1-2 μg/kg) has been to switch to or to add alternative agents or to increase the dose of dexmedetomidine (14, 15) . However, when such dose escalations are attempted, a higher incidence of hemodynamic effects such as bradycardia and hypotension has been noted. Given these issues, the addition of a second agent to dexmedetomidine rather than dose escalations may be the preferred option.
Procedural Sedation With Dexmedetomidine and Ketamine. Issues of concern when considering dexmedetomidine as an agent for procedural sedation include a long onset time, limited analgesic effect, and the potential for hemodynamic effects, including bradycardia and hypotension, especially when larger doses are administered. Although limited in number when compared to reports using only dexmedetomidine, there have been several reports in the literature regarding the use of a dexmedetomidine-ketamine combination for procedural sedation in the pediatric population (Table 1) (16) (17) (18) (19) . Two of these reports have been prospective randomized trials with a comparison to another sedation regimen (16, 17) . Tosun et al (16) compared a procedural sedation regimen that included dexmedetomidine and ketamine with one that combined propofol and ketamine. The study cohort included 44 children, ranging in age from 4 months to 16 yrs, with acyanotic congenital heart disease undergoing cardiac catheterization. Ketamine (1 mg/kg) and dexmedetomidine (1 μg/kg) were administered over 10 mins, followed by infusions of dexmedetomidine at 0.7 μg/kg/hr and ketamine at 1 mg/kg/hr. In the other arm of the study, propofol (1 mg/kg) and ketamine (1 mg/kg) were administered as the loading dose, followed by a propofol infusion at 100 μg/kg/hr and ketamine at 1 mg/kg/ hr. In both arms of the study, supplemental bolus doses of ketamine (1 mg/kg) were available as needed. Although sedation was effective with both regimens, the propofol-ketamine combination was superior. Patients sedated with dexmedetomidine-ketamine required more ketamine (2.03 ± 1.33 vs. 1.25 ± 0.67 mg/kg/ hr; p < .01) and more frequently required supplemental doses of ketamine (10/22 patients vs. 4/22 patients). Additionally, the recovery time was longer with dexmedetomidine and ketamine (median time, 45 vs. 20 mins; p = .01). No clinically significant differences in the hemodynamic or respiratory status were noted between the two groups.
Koruk et al (17) prospectively compared sedation using dexmedetomidine and ketamine to a regimen using midazolam and ketamine during extracorporeal shock wave lithotripsy in a cohort of 50 pediatric patients who ranged in age from 2 to 15 yrs. Patients received either a bolus dose of dexmedetomidine (1 μg/kg over 10 mins) and ketamine (1 mg/kg) or a bolus dose of midazolam (0.05 mg/kg) and ketamine (1 mg/kg). Patients were then observed by an anesthesiologist who was blinded to which medications they had received. Sedation was equally effective in both groups without clinically significant changes in the hemodynamic and respiratory parameters. Although there was no difference in the time to achieve an Aldrete score of 8, the times for eye opening, verbal (17) Prospective randomized trial comparing dexmedetomidineketamine with midazolam-ketamine in 50 pediatric patients for extracorporeal shock wave lithotripsy Sedation was equally effective in both groups. Times for eye-opening, verbal response, and cooperation were decreased in the dexmedetomidine-ketamine group. The incidence of nausea and vomiting was lower with dexmedetomidine-ketamine (4.7% vs. 32%). Mester et al (18) Retrospective case series using dexmedetomidine and ketamine for sedation during cardiac catheterization. No comparative group was included. The cohort included 16 children ranging in age from 16 mos to 15 yrs
No patients responded to infiltration of the groin with local anesthetic and placement of the arterial and venous cannulae. Three patients required a supplemental dose of ketamine. In two patients, the dexmedetomidine infusion was decreased because of heart rate changes. Two patients had development of upper airway obstruction that responded to repositioning of the airway. McVey and Tobias (19) Retrospective case series using dexmedetomidine and ketamine for sedation during lumbar puncture for spinal anesthesia. No comparative group was included. The study cohort included 12 children ranging in age from 2 to 9 yrs
The lumbar puncture for the performance of spinal anesthesia was tolerated in all of the patients. One patient required a decrease of the dexmedetomidine infusion for bradycardia. One patient required a fluid bolus for blood pressure of 68/38 mm Hg. Two patients had upper airway obstruction that resolved with repositioning of the airway.
response, and cooperation were decreased in the dexmedetomidine-ketamine group. Additionally, the incidence of nausea and vomiting was significantly lower with dexmedetomidine-ketamine compared with midazolam-ketamine (4.7% vs. 32%).
Two other large case series provide us with retrospective information regarding the combination of dexmedetomidine and ketamine for procedural sedation without a comparative group (18, 19) . Mester et al (18) retrospectively reviewed the use of dexmedetomidine and ketamine for sedation during cardiac catheterization in 16 children with congenital heart disease, ranging in age from 16 months to 15 yrs old. A bolus dose of ketamine (2 mg/kg) and dexmedetomidine (1 μg/kg) mixed in a single syringe was administered over 3 mins, followed by a continuous infusion 
No patient responded to infiltration of the groin and placement of the arterial and venous cannulae for cardiac catheterization. Three patients required a supplemental dose of ketamine (1 mg/kg). In two of these patients, the bolus dose of ketamine was administered before changing the vascular cannulae in the middle of the procedure. In two patients, the dexmedetomidine infusion was decreased from 2 to 1 μg/ kg/hr at 12-15 mins instead of 30 mins because of a decrease in heart rate. Two patients had development of upper airway obstruction that responded to repositioning of the airway. No central apnea was noted. Although the Paco 2 was ≥45 mm Hg in seven patients, the maximum value was 48 mm Hg.
More recently, McVey and Tobias (19) described their experience using these agents during lumbar puncture for spinal anesthesia in 12 pediatric patients. The dosing regimen was the same as that reported by Mester et al. The lumbar puncture for the performance of spinal anesthesia was tolerated in all of the patients without movement or the need for supplemental agent. The heart rate decrease was ≥20% from baseline in 5 of 12 patients, although only one patient required intervention with an early decrease of the dexmedetomidine infusion. One patient had a blood pressure decrease of 20% from baseline. This patient had fasted for over 10 hrs before surgery and had a low blood pressure reading of 68/38 mm Hg that responded to a fluid bolus of 10 mL/kg. Upper airway obstruction in two patients resolved with repositioning of the airway.
Additional information regarding the potential utility of a dexmedetomidineketamine combination is provided by Zor et al (20) in their study of 24 adults undergoing burn dressing changes. A secondary outcome of the study was to find the most effective means of limiting the adverse effects related to the administration of ketamine. Twenty-four adults were randomized into one of three groups. Group 1 received ketamine (2 mg/kg), group 2 received tramadol (1 mg/kg) followed 30 mins later by ketamine (2 mg/ kg) and dexmedetomidine (1 μg/kg), whereas group 3 received tramadol (1 mg/ kg) followed 30 mins later by ketamine (2 mg/kg) and midazolam (0.05 mg/kg). The authors reported improved analgesia and a decreased incidence of adverse effects, including emergence phenomena and hallucinations related to ketamine in patients who received dexmedetomidine (group 2).
Additional anecdotal experience in small retrospective case series or individual case reports have consistently demonstrated the utility of dexmedetomidine in conjunction with ketamine for procedures in which a deep level of sedation is required while maintaining spontaneous respiration (Table 2) (21) (22) (23) (24) (25) (26) (27) (28) . Several of these reports have included patients with significant comorbid conditions, including pulmonary hypertension, upper airway obstruction with sleep apnea, tracheal compression from a mediastinal mass, congenital heart disease, as well as compromised cardiac and respiratory function. These reports, which have included a total of 21 pediatric patients, demonstrate that a dexmedetomidine-ketamine combination effectively achieves the desired level of sedation while minimizing the potential for adverse effects.
CONCLUSION
Given its limited analgesic effects, dexmedetomidine does not appear to be the ideal agent for painful procedures. However, anecdotal experience and a few large series from the literature demonstrate the utility of a combination of dexmedetomidine with ketamine for procedural sedation. When used together, dexmedetomidine may limit the tachycardia, hypertension, salivation, and emergence phenomena from ketamine, whereas ketamine may prevent the bradycardia and hypotension that has been reported with dexmedetomidine (20, 29, 30) . Additionally, the addition of ketamine to dexmedetomidine to initiate the sedation process speeds the onset of sedation and eliminates the slow onset time when dexmedetomidine is used as the sole agent with the loading dose administered over 10 mins. When used in such a scenario, the two agents can be coadministered from a single syringe. Although various regimens have been reported in the literature, the most effective regimen appears to be the use of a bolus dose of both agents, dexmedetomidine (1 μg/kg) and ketamine (1-2 mg/kg), to initiate sedation. This can then be followed by a dexmedetomidine infusion (1-2 μg/kg/ hr) with supplemental bolus doses of ketamine (0.5-1 mg/kg) as needed. Although still relatively preliminary, the current literature supports the potential utility of the combination of ketamine and dexmedetomidine for procedural sedation, even in patients with compromised respiratory or cardiac function. When compared with other agents used for procedural sedation, these two agents have limited effects on ventilatory function when compared with other more commonly used agents (4, 31) . Future studies may take one of two directions. Because there are no direct comparisons of dexmedetomidine as the sole agent for sedation vs. a dexmedetomidine-ketamine combination, this may be one venue. If the dexmedetomidineketamine combination is superior, then direct comparisons to other commonly used regimens (propofol) appear warranted for both invasive and noninvasive procedures. Given the increased cost of a dexmedetomidine regimen, whenever such studies are performed, attention to the cost-benefits ratio including manpower issues of recovery times should be included.
